Skip to content
10-Q

Quarterly Report

Quince Therapeutics, Inc. QNCX

0001193125-26-217098

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 16.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 9.19M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 4.39M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $148K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$7.63M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.6M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $18.03M
Short Term Investments Q1 2026 · Mar 31, 2026 $0
Short Term Investments Q1 2026 · Dec 31, 2025 $11.94M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $18.16M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.81M
Stockholders Equity Q1 2026 · Mar 31, 2026 $15.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$35.71M
Stockholders Equity Q1 2026 · Mar 31, 2025 $18.58M
Stockholders Equity Q1 2026 · Dec 31, 2024 $30.15M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.77M
Current Liabilities Q1 2026 · Dec 31, 2025 $43.23M
Total Liabilities Q1 2026 · Mar 31, 2026 $10.95M
Total Liabilities Q1 2026 · Dec 31, 2025 $129.24M
Current Assets Q1 2026 · Mar 31, 2026 $25.58M
Current Assets Q1 2026 · Dec 31, 2025 $22.9M
Total Assets Q1 2026 · Mar 31, 2026 $26.62M
Total Assets Q1 2026 · Dec 31, 2025 $93.52M
Eps Diluted Q1 2026 · Mar 31, 2026 $2.88
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.42
Eps Basic Q1 2026 · Mar 31, 2026 $3.60
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.42
Sga Expense Q1 2026 · Mar 31, 2026 $4.27M
Sga Expense Q1 2026 · Mar 31, 2025 $4.79M
Rd Expense Q1 2026 · Mar 31, 2026 $6.85M
Rd Expense Q1 2026 · Mar 31, 2025 $8.15M
Net Income Q1 2026 · Mar 31, 2026 $35.91M
Net Income Q1 2026 · Mar 31, 2025 −$15.03M
Operating Income Q1 2026 · Mar 31, 2026 −$14.59M
Operating Income Q1 2026 · Mar 31, 2025 −$14.86M